Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145408063> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2145408063 endingPage "808" @default.
- W2145408063 startingPage "806" @default.
- W2145408063 abstract "Cutaneous adverse drug reactions (cADRs) can cause significant morbidity and distress in patients, especially in the HIV-infected population on antiretroviral therapy. Adverse drug reaction monitoring and ascertaining causality in resource-limited settings remain serious challenges. This study was conducted to evaluate causality and measure the incidence of cADRs in HIV-infected patients on highly active antiretroviral therapy. The study was also designed to test a three-step approach in the monitoring and evaluation of ADRs in resource-limited settings.A retrospective review of patient medical records was performed at the Parirenyatwa Family Care Centre, Harare, Zimbabwe. Cases of cADRs were reported to the Medicines Control Authority of Zimbabwe, the main drug regulating body in Zimbabwe, for assessment and causality classification.We reviewed 221 randomly selected patient records to determine whether any diagnoses of cADRs were made by clinicians. Causality assessment revealed that 13.1% of cADRs were due to an offending agent in the antiretroviral therapy versus an initial incidence of 17.6% which had been determined by the physicians.cADRs had an incidence of 13.1% within the population under study due to non nucleoside reverse transcriptase inhibitors (NNRTIs). Most reactions were caused by the NNRTIs which contributed 72.4 % of all cADRs. A panel of experts from the drug regulatory authority can be used as an implementation based mechanism in ascertaining causality objectively in settings where resources are constrained." @default.
- W2145408063 created "2016-06-24" @default.
- W2145408063 creator A5029493379 @default.
- W2145408063 creator A5039488889 @default.
- W2145408063 creator A5060924023 @default.
- W2145408063 creator A5075585167 @default.
- W2145408063 creator A5077187788 @default.
- W2145408063 date "2012-11-26" @default.
- W2145408063 modified "2023-09-27" @default.
- W2145408063 title "Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program" @default.
- W2145408063 cites W2169865372 @default.
- W2145408063 doi "https://doi.org/10.3855/jidc.1908" @default.
- W2145408063 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3535441" @default.
- W2145408063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23277506" @default.
- W2145408063 hasPublicationYear "2012" @default.
- W2145408063 type Work @default.
- W2145408063 sameAs 2145408063 @default.
- W2145408063 citedByCount "2" @default.
- W2145408063 countsByYear W21454080632021 @default.
- W2145408063 countsByYear W21454080632022 @default.
- W2145408063 crossrefType "journal-article" @default.
- W2145408063 hasAuthorship W2145408063A5029493379 @default.
- W2145408063 hasAuthorship W2145408063A5039488889 @default.
- W2145408063 hasAuthorship W2145408063A5060924023 @default.
- W2145408063 hasAuthorship W2145408063A5075585167 @default.
- W2145408063 hasAuthorship W2145408063A5077187788 @default.
- W2145408063 hasBestOaLocation W21454080631 @default.
- W2145408063 hasConcept C120665830 @default.
- W2145408063 hasConcept C121332964 @default.
- W2145408063 hasConcept C126322002 @default.
- W2145408063 hasConcept C177713679 @default.
- W2145408063 hasConcept C197934379 @default.
- W2145408063 hasConcept C2780035454 @default.
- W2145408063 hasConcept C2780542314 @default.
- W2145408063 hasConcept C2908647359 @default.
- W2145408063 hasConcept C2993432071 @default.
- W2145408063 hasConcept C57658597 @default.
- W2145408063 hasConcept C61511704 @default.
- W2145408063 hasConcept C62520636 @default.
- W2145408063 hasConcept C64357122 @default.
- W2145408063 hasConcept C71924100 @default.
- W2145408063 hasConcept C98274493 @default.
- W2145408063 hasConcept C99454951 @default.
- W2145408063 hasConceptScore W2145408063C120665830 @default.
- W2145408063 hasConceptScore W2145408063C121332964 @default.
- W2145408063 hasConceptScore W2145408063C126322002 @default.
- W2145408063 hasConceptScore W2145408063C177713679 @default.
- W2145408063 hasConceptScore W2145408063C197934379 @default.
- W2145408063 hasConceptScore W2145408063C2780035454 @default.
- W2145408063 hasConceptScore W2145408063C2780542314 @default.
- W2145408063 hasConceptScore W2145408063C2908647359 @default.
- W2145408063 hasConceptScore W2145408063C2993432071 @default.
- W2145408063 hasConceptScore W2145408063C57658597 @default.
- W2145408063 hasConceptScore W2145408063C61511704 @default.
- W2145408063 hasConceptScore W2145408063C62520636 @default.
- W2145408063 hasConceptScore W2145408063C64357122 @default.
- W2145408063 hasConceptScore W2145408063C71924100 @default.
- W2145408063 hasConceptScore W2145408063C98274493 @default.
- W2145408063 hasConceptScore W2145408063C99454951 @default.
- W2145408063 hasIssue "11" @default.
- W2145408063 hasLocation W21454080631 @default.
- W2145408063 hasLocation W21454080632 @default.
- W2145408063 hasLocation W21454080633 @default.
- W2145408063 hasLocation W21454080634 @default.
- W2145408063 hasOpenAccess W2145408063 @default.
- W2145408063 hasPrimaryLocation W21454080631 @default.
- W2145408063 hasRelatedWork W2009737011 @default.
- W2145408063 hasRelatedWork W2289010737 @default.
- W2145408063 hasRelatedWork W2325205130 @default.
- W2145408063 hasRelatedWork W2377540513 @default.
- W2145408063 hasRelatedWork W2384569975 @default.
- W2145408063 hasRelatedWork W3113386111 @default.
- W2145408063 hasRelatedWork W4282585499 @default.
- W2145408063 hasRelatedWork W4298082289 @default.
- W2145408063 hasRelatedWork W56637561 @default.
- W2145408063 hasRelatedWork W2186394847 @default.
- W2145408063 hasVolume "6" @default.
- W2145408063 isParatext "false" @default.
- W2145408063 isRetracted "false" @default.
- W2145408063 magId "2145408063" @default.
- W2145408063 workType "article" @default.